Literature DB >> 1663497

Benzodiazepines inhibit neutrophil chemotaxis and superoxide production in a stimulus dependent manner; PK-11195 antagonizes these effects.

M Finnerty1, T J Marczynski, H J Amirault, M Urbancic, B R Andersen.   

Abstract

Diazepam, which binds both central (neuronal) and peripheral (non-neuronal) benzodiazepine binding sites, and Ro5-4864, a ligand selective for benzodiazepine peripheral binding sites (PBS), both inhibited the FMLP induced chemotaxis in human neutrophils at concentrations as low as 10(-8) M. A selective peripheral benzodiazepine antagonist, PK-11195 (10(-5) M), partially reversed the benzodiazepine inhibition of chemotaxis. Diazepam also inhibited the superoxide production induced by FMLP, NaF, and A23187, but not that induced by PMA whose stimulant action was insensitive even to 10(-4) M diazepam. The FMLP-induced superoxide production was most sensitive to diazepam inhibition (ID50 = 2.25 x 10(-6) M diazepam); the effect of NaF was slightly less sensitive (ID50 = 1.34 x 10(-5) M diazepam); and the effect of A23187 was least sensitive as it was suppressed only at 10(-4) M diazepam concentrations. Like diazepam, Ro5-4864 inhibited the FMLP-induced superoxide production, and PK-11195 (10(-5) M) significantly antagonized both diazepam and Ro5-4864 inhibition. Binding studies showed the presence of a saturable benzodiazepine 'peripheral' type binding site (PBS) on human neutrophils with a Kd of 1.2 +/- 0.06 x 10(-8) M (+/- SEM), and a Bmax of 1028 +/- 86.2 fmol/10(6) cells (+/- SEM) for [3H]Ro5-4864; the binding was displaceable by PK-11195, Ro5-4864 and diazepam but not by clonazepam.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663497     DOI: 10.1016/0162-3109(91)90043-x

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  6 in total

1.  Dexmedetomidine-induced neuroprotection: is it translational?

Authors:  Yunzhen Wang; Ruquan Han; Zhiyi Zuo
Journal:  Transl Perioper Pain Med       Date:  2016

Review 2.  The Role of miRNAs in Dexmedetomidine's Neuroprotective Effects against Brain Disorders.

Authors:  Codrin-Constantin Burlacu; Maria-Adriana Neag; Andrei-Otto Mitre; Alexandru-Constantin Sirbu; Andrei-Vlad Badulescu; Anca-Dana Buzoianu
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

3.  Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial.

Authors:  Pratik P Pandharipande; Robert D Sanders; Timothy D Girard; Stuart McGrane; Jennifer L Thompson; Ayumi K Shintani; Daniel L Herr; Mervyn Maze; E Wesley Ely
Journal:  Crit Care       Date:  2010-03-16       Impact factor: 9.097

4.  Increased plasma levels of endozepines, endogenous ligands of benzodiazepine receptors, during systemic inflammation: a prospective observational study.

Authors:  Thomas Clavier; Marie-Christine Tonon; Anne Foutel; Emmanuel Besnier; Antoine Lefevre-Scelles; Fabrice Morin; Pierrick Gandolfo; Jean-Jacques Tuech; Muriel Quillard; Benoit Veber; Bertrand Dureuil; Hélène Castel; Vincent Compère
Journal:  Crit Care       Date:  2014-11-18       Impact factor: 9.097

5.  Benzodiazepine and Z-drug use and risk of pneumonia in patients with chronic kidney disease: A population-based nested case-control study.

Authors:  Meng-Ting Wang; Yun-Han Wang; Hsin-An Chang; Chen-Liang Tsai; Ya-Sung Yang; Chen Wei Lin; Cheng-Chin Kuo; Yu-Juei Hsu
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

6.  Benzodiazepine augmented γ-amino-butyric acid signaling increases mortality from pneumonia in mice.

Authors:  Robert D Sanders; Alexandra Godlee; Toshifumi Fujimori; John Goulding; Gang Xin; Samira Salek-Ardakani; Robert J Snelgrove; Daqing Ma; Mervyn Maze; Tracy Hussell
Journal:  Crit Care Med       Date:  2013-07       Impact factor: 9.296

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.